| Literature DB >> 35287314 |
Uwe Lendeckel1, Simone Venz1, Carmen Wolke1.
Abstract
Macrophages are cells of the innate immune system and represent an important component of the first-line defense against pathogens and tumor cells. Here, their diverse functions in inflammation and tumor defense are described, and the mechanisms, tools, and activation pathways and states applied are presented. The main focus is on the role and origin of reactive oxygen species (ROS), the important signal pathways TLR/NF-κB, and the M1/M2 polarization of macrophages.Entities:
Keywords: M1 macrophage; M2 macrophage; NF-κB signal transduction pathway; Oxidative burst; Phagocytosis; Reactive oxygen species; TLR4 signaling
Year: 2022 PMID: 35287314 PMCID: PMC8907910 DOI: 10.1007/s40828-022-00163-4
Source DB: PubMed Journal: ChemTexts ISSN: 2199-3793
Fig. 1Activation of circulatory monocytes in response to variety of stimuli causes differentiation into macrophages. The shapes of macrophages are as diverse as their phenotypes and functions
Fig. 2Hematopoiesis. Myeloid and lymphatic precursor cells develop from self-renewing, pluripotent hematopoietic stem cells. From these progenitor cells, lymphocytes and various myeloid cells develop, which represent the cellular arsenal of the immune system (with kind permission [75])
Macrophage subtypes originating from their polarization [17, 18]
| Macrophage type | Macrophage Subtype | Induction by | Surface markers | Cellular markers | Production of cytokines |
|---|---|---|---|---|---|
| M1 “classically activated” | M1 | LPS, IFNγ, TNFα, GM-CSF | CD68, CD80, CD86, IL-1R, TLR2, TLR4, iNOS, IFNγR, MHC IIhigh, Fc-RI/II/III | NF-κB, STAT1, STAT5, IRF3, IRF5 | IL-1α, IL-1β, IL-6, IL-12, IL-18, TNFα, M-CSF |
| Diabetes/obesity-associated (M1?) | Insulin resistance, persistent & hyper-inflammatory activation | BCA1, CD11c, CD36 | PLIN2, Msr1A | ||
| M2 “alternatively activated” | M2a | IL-4, IL-13 | CD200, IL-1RII, Dectin-1, MHC IIlow | IRF4, PPARγ, STAT6 | IL-10, IL-1Ra, TGFβ |
| M2b | Immune complexes + TLR/IL-1β | CD86, MHC IIlow | IRF4, SOCS3 | IL-1β, IL-6, IL-10, TNFα | |
| M2c | IL-10, TGFβ | CD163, CD206, TLR1 | IRF4, SOCS3 | IL-10, TGFβ |
Different types of tissue-resident macrophages
| Tissue | Macrophage |
|---|---|
| Liver | Kupffer cells |
| Lung | Alveolar macrophages, pneumocytes type II |
| Skin | Langerhans cells |
| Serous cavities | Serous macrophages |
| Connective tissue | Histiocytes |
| Joints/cartilage | Synovial cells (type A) |
| Bone | Osteoclasts |
| Kidney | Mesangium macrophages |
| Brain | Microglia |
Macrophage receptors involved in phagocytosis
| Fcγ receptor ligand affinity | Ligand | Affinity |
|---|---|---|
| FcγRI (CD64) | IgG1, IgG3 (IgG4, IgG2) | High |
| FcγRII (CD32) | IgG1, IgG3 (IgG4, IgG2) | Low |
| FcγRIII (CD16) | IgG1, IgG3 | Low |
Fig. 3Processing of protein antigens: the MHC-II pathway. Protein antigens are taken up by antigen-presenting cells (APC) into endosomes, which then fuse with lysosomes. There the proteins are broken down into protein fragments. After their synthesis in the ER, MHC-II molecules are transported in vesicles. Newly synthesized MHC-II molecules carry a peptide that occupies the antigen binding site and is called CLIP (class II invariant chain peptide). If both vesicles fuse, CLIP is released from the peptide binding site of the MHC-II by the protein DM and MHC-II can now bind antigen fragments. These MHC-II/peptide complexes are then transported to the cell membrane and can be recognized by CD4-positive cells ([75] with kind permission)
Fig. 4Toll-like receptors (TLRs) and their ligand specificity. Different TLRs and their ligand specificity. TLRs recognize a variety of pathogen-associated structures (PAMPs). The recognition of LPS by TLR-4 requires the accessory proteins CD14 and MD-2. TLR-2 recognizes very different ligands and interacts with TLR-6 and TLR-1. TLR-3 is involved in the recognition of viral double-stranded RNA (dsRNA), TLR-5 binds flagellin, a protein of bacterial flagella, and TLR-9 recognizes bacterial DNA on the basis of its unmethylated CpG motifs ([76] with kind permission)
Fig. 5Signal transduction pathways of Toll-like receptors. The binding of the ligand (LPS/LBP/CD14; MD-2) to TLR leads to the association of adapter molecules such as MyD88, Toll-interacting Protein (TOLLIP), the protein kinase IRAK, and TRAF6 (TNF-receptor associated factor 6). TRAF6 activates IκB kinases 1 and 2 (IKK-1/2) via the kinase TAK1 (TGF-β activated kinase). These kinases phosphorylate IκB, which leads to the degradation of the inhibitory protein and releases NF-κB as a dimer. NF-κB migrates into the cell nucleus and induces a transcriptional activation of proinflammatory and immunomodulatory genes ([76] with kind permission)